menu
    • menu
    [{"orgOrder":0,"company":"Theolytics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"THEO-260","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Theolytics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Theolytics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Theolytics \/ Undisclosed"},{"orgOrder":0,"company":"Theolytics","sponsor":"Innovate Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Microorganism","year":"2024","type":"Funding","leadProduct":"THEO-260","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Theolytics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Theolytics \/ Innovate Biopharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Theolytics \/ Innovate Biopharmaceuticals"},{"orgOrder":0,"company":"Theolytics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"THEO-260","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Theolytics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Theolytics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Theolytics \/ Undisclosed"},{"orgOrder":0,"company":"Theolytics","sponsor":"Sound Bioventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Microorganism","year":"2024","type":"Financing","leadProduct":"THEO-260","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Theolytics","amount2":0.02,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Injection","sponsorNew":"Theolytics \/ Sound Bioventures","highestDevelopmentStatusID":"7","companyTruncated":"Theolytics \/ Sound Bioventures"},{"orgOrder":0,"company":"Theolytics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"THEO-260","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Theolytics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theolytics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Theolytics \/ Undisclosed"},{"orgOrder":0,"company":"Theolytics","sponsor":"Epidarex Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Theolytics","amount2":0.01,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Theolytics \/ Epidarex Capital","highestDevelopmentStatusID":"3","companyTruncated":"Theolytics \/ Epidarex Capital"},{"orgOrder":0,"company":"Theolytics","sponsor":"M Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Theolytics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Theolytics \/ M Ventures","highestDevelopmentStatusID":"3","companyTruncated":"Theolytics \/ M Ventures"},{"orgOrder":0,"company":"Theolytics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Microorganism","year":"2025","type":"Inapplicable","leadProduct":"THEO-260","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Theolytics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Theolytics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Theolytics \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Theolytics

    Menu

    Theolytics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Theolytics

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Theolytics

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : THEO-260

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Trial of THEO-260 (Administered Via Intraperitoneal Route) in Ovarian Cancer Patients

                            Details : THEO-260 is a Microorganism drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Ovarian Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Microorganism

                            Upfront Cash : Inapplicable

                            October 08, 2025

                            Lead Product(s) : THEO-260

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Theolytics

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Theolytics

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : THEO-260

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Theolytics Doses First Patient in Phase I/IIa Trial of THEO-260 in Ovarian Cancer

                            Details : THEO-260 is a next-generation oncolytic adenovirus candidate being investigated for advanced-stage platinum-resistant ovarian cancer in 18 year and above.

                            Product Name : Undisclosed

                            Product Type : Microorganism

                            Upfront Cash : Inapplicable

                            November 19, 2024

                            Lead Product(s) : THEO-260

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Theolytics

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Theolytics

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : THEO-260

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Trial of THEO-260 in Ovarian Cancer Patients

                            Details : THEO-260 is a Microorganism drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Ovarian Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Microorganism

                            Upfront Cash : Inapplicable

                            October 01, 2024

                            Lead Product(s) : THEO-260

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Theolytics

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Theolytics

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : THEO-260

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Innovate Biopharmaceuticals

                            Deal Size : $2.2 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Theolytics Awarded Significant £2M Transforming Cancer Therapeutics Grant from Innovate UK

                            Details : The proceeds will be used to support the clinical development of its lead candidate THEO-260, a next-generation oncolytic adenovirus for the treatment of ovarian cancer.

                            Product Name : Undisclosed

                            Product Type : Microorganism

                            Upfront Cash : Undisclosed

                            September 02, 2024

                            Lead Product(s) : THEO-260

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Innovate Biopharmaceuticals

                            Deal Size : $2.2 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Theolytics

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Theolytics

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : THEO-260

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Sound Bioventures

                            Deal Size : $24.5 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Theolytics Raises £19M in Latest Financing, Welcomes Sound Bioventures

                            Details : The proceeds from the financing round further strengthen the company’s position as it advances its lead oncolytic adenovirus, THEO-260, a next-generation oncolytic adenovirus, for ovarian cancer.

                            Product Name : Undisclosed

                            Product Type : Microorganism

                            Upfront Cash : Undisclosed

                            April 17, 2024

                            Lead Product(s) : THEO-260

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Sound Bioventures

                            Deal Size : $24.5 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Theolytics

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Theolytics

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : THEO-260

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Theolytics Presents CAF-Targeting Therapy For Stromal Rich Tumours, And Strengthens Leadership Team

                            Details : THEO-260 is a new oncolytic virus in development that is intrinsically capable of targeted killing of both cancer cells and cancer associated fibroblasts (CAFs).

                            Product Name : Undisclosed

                            Product Type : Microorganism

                            Upfront Cash : Inapplicable

                            October 06, 2022

                            Lead Product(s) : THEO-260

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Theolytics

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Theolytics

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Sponsor : M Ventures

                            Deal Size : Undisclosed

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Theolytics Expands Series A Financing and Welcomes M Ventures as a New Investor

                            Details : The expanded Series A funding will support the progress of internal programmes in ovarian cancer, and a second cancer indication in addition to further advancing the company's unique technology platforms.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            July 08, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Sponsor : M Ventures

                            Deal Size : Undisclosed

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Theolytics

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Theolytics

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Sponsor : Epidarex Capital

                            Deal Size : $6.8 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Theolytics Raises $6.8 million Series A Round Co-Led by Epidarex Capital and Taiho Ventures to Advance Viral C...

                            Details : The financing will be used to progress the company’s Oncolytic viral therapies towards human clinical trials.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            January 07, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Sponsor : Epidarex Capital

                            Deal Size : $6.8 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth